{"id":390713,"date":"2018-03-29T00:00:00","date_gmt":"2018-03-29T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0008-2018-biopharma-systemic-lupus-erythematosus-unmet-need-us-eu-2018\/"},"modified":"2026-04-16T11:26:19","modified_gmt":"2026-04-16T11:26:19","slug":"unneim0008-2018-biopharma-systemic-lupus-erythematosus-unmet-need-us-eu-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0008-2018-biopharma-systemic-lupus-erythematosus-unmet-need-us-eu-2018\/","title":{"rendered":"Systemic Lupus Erythematosus | Unmet Need | US\/EU | 2018"},"content":{"rendered":"<p><strong>MARKET OUTLOOK<\/strong><\/p>\n<p>Systemic lupus erythematosus (<abbr title=\"systemic lupus erythematosus\">SLE<\/abbr>) is an autoimmune disease that can affect different organ systems of the body and manifest in\u00a0a wide spectrum of clinical symptoms ranging from general fatigue to serious renal and <abbr title=\"central nervous system\">CNS<\/abbr> manifestations. Most of the drugs used to treat <abbr title=\"systemic lupus erythematosus\">SLE<\/abbr> are old, generically available, and prescribed off-label. To date, Benlysta is the only drug approved for moderate to severe <abbr title=\"systemic lupus erythematosus\">SLE<\/abbr> (excluding severe active renal and severe active <abbr title=\"central nervous system\">CNS<\/abbr>). The\u00a0high unmet need in this indication suggests\u00a0significant commercial opportunity for novel therapies offering a better profile than that of Benlysta.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What are the treatment drivers and goals for moderate to severe <abbr title=\"systemic lupus erythematosus\">SLE<\/abbr> (excluding severe active renal and severe active <abbr title=\"central nervous system\">CNS<\/abbr>)?<\/li>\n<li>What drug attributes are key influences, which have limited impact, and which are hidden opportunities?<\/li>\n<li>How do current therapies perform on key treatment drivers and goals for moderate to severe <abbr title=\"systemic lupus erythematosus\">SLE<\/abbr> (excluding severe active renal and severe active <abbr title=\"central nervous system\">CNS<\/abbr>)?<\/li>\n<li>What are the prevailing areas of unmet need and opportunity in moderate to severe <abbr title=\"systemic lupus erythematosus\">SLE<\/abbr> (excluding severe active renal and severe active <abbr title=\"central nervous system\">CNS<\/abbr>)?<\/li>\n<li>What trade-offs across different clinical attributes and prices are acceptable to U.S. and European rheumatologists for a hypothetical new drug for moderate to severe <abbr title=\"systemic lupus erythematosus\">SLE<\/abbr> (excluding severe active renal and severe active <abbr title=\"central nervous system\">CNS<\/abbr>)?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.<\/p>\n<p><strong>Markets covered:<\/strong> United States, United Kingdom, France, Germany<\/p>\n<p><strong>Primary research: <\/strong>Survey of 60 U.S. and 31 European rheumatologists fielded in December 2017<\/p>\n<p><strong>Key companies:<\/strong> Bristol-Myers Squibb, GlaxoSmithKline, Roche<\/p>\n<p><strong>Key drugs: <\/strong> Azathioprine, Benlysta (belimumab), CellCept (mycophenolate mofetil), cyclophosphamide, hydroxychloroquine, methotrexate, Rituxan\/MabThera (rituximab)<\/p>\n","protected":false},"template":"","class_list":["post-390713","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-systemic-lupus-erythematosus","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390713","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390713\/revisions"}],"predecessor-version":[{"id":393837,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390713\/revisions\/393837"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390713"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}